Cipla Ltd · NSE:CIPLA
Cipla — Q1 FY2017 Earnings Presentation
11 slides from Cipla's earnings presentation, Aug 12, 2016
Slide 1: Investor Presentation Q1 FY17 Earnings Release
Investor Presentation Q1 FY 17 Earnings Release 12 August 2016 Investor Presentation Q1 FY 17 Earnings Release Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Key Highlights for the quarter
Key Highlights for the quarter Q1 FY17 Highlights Continued Growth Momentum in Key Markets Leadership position Strong base business Healthy double digit in a challenging India performance in US1 growth in South Africa2 Market EBITDA percentage expansion on the base business highlighting early Profit
Slide 4: Financial Performance
Financial Performance Q1 FY17 (Consolidated) Revenue Break-up Actuals vs Q1 FY Global Others, (Rs Cr) 16 2% API, 4% Total Income from India, 40% 3,594 -6% Emerging Operations Mkts, 21% a) Domestic Sales 1,449 5% b) Int’l Sales 2,051 -14% c) Other Operating Income 94 21% Europe, EBITDA 611 -42% 4% EB
Slide 5: India Sales
India Sales India Sales Rs Cr As per IMS MAT Jun’16, strong domestic growth of 1600 ~13% with 5.2% market share in Rx 1449 1381 1400 5% Robust performance despite regulatory challenges 1200 − Key therapies such as Respiratory and Anti- 19% 1000 infective have outperformed the market2 21% 800 S
Slide 6: South Africa
South Africa South Africa Sales ZAR Mn As per IMS MAT (Jun’16), growth of ~14% vs. ~7% 1000 905 market growth in private market, among the Top 3 900 fastest-growing players 800 742 22% – Leadership in Respiratory, CNS, Oncology 700 segments with ~25-30% market share 600 Market share of 5.3% in p
Slide 7: North America
North America North America Sales $ Mn Base business growth of 30%+ in dollar terms vs 132 last year Third fastest-growing generics player in the US in 98 Q1 FY172, strong DTM performance - 8 of 38 products ranked #1 in their segments Integration of InvaGen Pharmaceuticals Inc. and Exelan Phar
Slide 8: Emerging Markets
Emerging Markets Emerging Markets Sales $ Mn Decline of ~13% in DTM markets vs. last year, 140 driven by forex volatility and complexity reduction 128 -11% 113 initiatives 120 Decline of ~15% in partnership-led markets (B2B), 100 mainly on account of price decline in some Middle 80 East markets
Slide 9: Europe and API
Europe and API Europe Sales $ Mn 50 Sales largely flat vs. last year, driven by 40 country-specific challenges in B2B business 30 Progress on transition from DTM to B2B 21.2 21 20 -1% (partnering) model in select countries 10 Focus on profitability through product mix 0 Q1 FY 16 Q1 FY 17 impro
Slide 10: Progress on key priorities is on track
Progress on key priorities is on track Key Priorities Q1 FY17 Progress ~6x growth in organic US DTM business; 6 from Cipla pipeline in last six months Seamless integration of InvaGen and Exelan businesses - Processes integrated across key functions (Commercial, Quality, Manufacturing etc.) 1 A
Slide 11: Thank you
Thank you Contact details: Alpesh Dalal Contact No: +91-22–24826460 E-Mail: alpesh.dalal@cipla.com Investor Presentation Q1 FY 17 Earnings Release Confidential 11